{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:18:29Z","timestamp":1787649509739,"version":"build-2736575974"},"reference-count":21,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Int J Surg Pathol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>\n                    <jats:bold>Introduction:<\/jats:bold>\n                    Selected patients with pelvic high-grade serous carcinoma (HGSC) receive neoadjuvant chemotherapy prior to resection. Guidelines allow cytopathology fluids to be used to confirm this diagnosis before neoadjuvant chemotherapy, which can be less invasive and costly. This study examines how often cytology fluids are used for this purpose at our institution.\n                    <jats:bold>Methods:<\/jats:bold>\n                    Specimens of HGSC on cytology were searched for over 3 years.\n                    <jats:bold>Results:<\/jats:bold>\n                    Of 54 specimens, 44 of 54 (81%) were effusions, 10 of 54 (19%) were washings. The majority (32\/54; 59%) of specimens were abdominal, the remaining were pleural (22\/54; 41%). Most 32 of 54 (59%) were post therapy\/diagnosis. A minority of specimens (14\/54; 26%) had a concurrent surgical pathology specimen. In all, 34 of 52 (65%) patients were Stage 3, 13 of 52 (25%) Stage 4, and 5 of 52 (10%) Stage 2. Only 6 of 54 (11%) specimens were used solely for initial diagnosis with no concurrent surgical pathology specimen. All 6 were effusions; 5 of 6 (83%) were abdominal and 1 of 6 (17%) was pleural. Immunohistochemistry was performed on a majority (30\/54; 56%) of specimens, with PAX8 being the most common, (30\/54; 56%) and was positive in all specimens. Mutational p53 staining was noted in 20 of 21 (95%) specimens.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Cytology fluid alone is uncommonly used for diagnosis of HGSC prior to initiation of neoadjuvant chemotherapy at our institution, possibly due to morphologic overlap on fluid specimens and relatively new implementation of neoadjuvant chemotherapy guidelines. High-grade serous carcinoma is most often encountered in effusions post-therapy. Morphology is similar in all specimens, regardless of preparation method or therapy status.\n                  <\/jats:p>","DOI":"10.1177\/10668969251362188","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T07:06:19Z","timestamp":1755587179000},"page":"80-86","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["The Use of Cytology Specimens in Isolation for Diagnosis of High-Grade Serous Carcinoma Prior to Initiation of Neoadjuvant Chemotherapy: A 3-Year Experience at a Large Referral Hospital"],"prefix":"10.1177","volume":"34","author":[{"given":"Sameer Chhetri","family":"Aryal","sequence":"first","affiliation":[{"name":"The Cleveland Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2387-1274","authenticated-orcid":false,"given":"Natalie","family":"Banet","sequence":"additional","affiliation":[{"name":"The Cleveland Clinic"},{"name":"The Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"e_1_3_2_2_2","volume-title":"Female Genital Tumors","author":"WHO Female Reproductive Editorial Board","year":"2020","unstructured":"WHO Female Reproductive Editorial Board. Female Genital Tumors. IARC; 2020."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908806"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62223-6"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.5212"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/his.13399"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.02.023"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqaa028"},{"issue":"1","key":"e_1_3_2_9_2","article-title":"Data set for the reporting of ovarian, fallopian tube and primary peritoneal carcinoma: recommendations from the international collaboration on cancer reporting (ICCR)","volume":"41","author":"Gilks CB","year":"2022","unstructured":"Gilks CB, Selinger CI, Davidson B, et al. Data set for the reporting of ovarian, fallopian tube and primary peritoneal carcinoma: recommendations from the international collaboration on cancer reporting (ICCR). Int J Gynecol Pathol. 2022;41(Suppl 1):S119-S142.","journal-title":"Int J Gynecol Pathol"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2016.01.006"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.13878"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000522211"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPU0FION3RKKFO"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001545"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.20071"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.55.1.27"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(03)00376-7"},{"issue":"6","key":"e_1_3_2_18_2","first-page":"609","article-title":"Ovarian cancer: an overview","volume":"80","author":"Roett MA","year":"2009","unstructured":"Roett MA, Evans P. Ovarian cancer: an overview. Am Fam Physician. 2009;80(6):609-616.","journal-title":"Am Fam Physician"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.25259\/CMAS_02_07_2021"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.4103\/cytojournal.cytojournal_20_18"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.4103\/cytojournal.cytojournal_37_18"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jasc.2020.05.015"}],"container-title":["International Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10668969251362188","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10668969251362188","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10668969251362188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:20:03Z","timestamp":1787646003000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10668969251362188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1177\/10668969251362188"],"URL":"https:\/\/doi.org\/10.1177\/10668969251362188","relation":{},"ISSN":["1066-8969","1940-2465"],"issn-type":[{"value":"1066-8969","type":"print"},{"value":"1940-2465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]}}}